Targeted fungus fight: a genetic approach to taming Crohn's
NCT ID NCT04966585
Summary
This study tested whether treating a specific gut fungus with the antifungal drug posaconazole could reduce inflammation in people with active Crohn's disease who have a particular genetic risk (CARD9 S12N). It was a small, placebo-controlled trial that looked for improvements in gut lining and symptoms. The trial was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center (CSMC)
Los Angeles, California, 90048, United States
-
Mayo Clinic
Rochester, Minnesota, 55901, United States
Conditions
Explore the condition pages connected to this study.